Ask AI
Combining Therapeutic Approaches in Metastatic CRPC

CE / CME

Complementing PARP Inhibition in Metastatic CRPC: Expert Insights and Strategies for Combining Therapeutic Approaches

ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: June 19, 2025

Expiration: December 18, 2025

Pretest

Progress
1 2
Course Completed
1.

Based on current ASCO guidelines, which of the following best describes the recommended approach to testing for HRR alterations in patients with metastatic prostate cancer?

2.

For a 65-yr-old patient with mCRPC who has progressed after treatment with an ARPI and is found to have a somatic BRCA2 deletion, which of the following would you recommend (assuming all options are easily available)?

3.

A 72-yr-old man presents with de novo metastatic prostate cancer. After initial ADT and docetaxel, he develops castration resistance. He has tissue testing performed and is found to have a PALB2 mutation. Based on current FDA approvals, what treatment would you consider next?

4.

Patient Case: 66-Yr-Old Man With Anemia



  • A 66-yr-old man was diagnosed with T3 by DRE and mpMRI, N1 M1a, low-volume mHSPC

    • Initially managed with ADT alone; declined ARPI at the time

    • PSA began to rise (12 mo: 0.2; 18 mo: 1.2, 24 mo: 14.4)

    • Bone and CT scan: new lesions and progression of lymph nodes

    • Genetic testing identified a pathogenic germline BRCA2 mutation



  • He began a PARP inhibitor + ARPI combination 4 wk ago

    • Now reports fatigue, dizziness with standing, shortness of breath, headache

    • He is diagnosed with grade 3 anemia




In addition to transfusing packed red blood cells, which of the following would you recommend for managing this patient’s grade 3 anemia in your current practice?